EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

EnteroMedics, Inc. reports financial results for the quarter ended June 30, 2016.

We analyze the earnings along side the following peers of EnteroMedics, Inc. – LivaNova Plc, Boston Scientific Corporation, NeuroMetrix, Inc., St. Jude Medical, Inc., Abbott Laboratories, Johnson & Johnson and Natus Medical Incorporated (LIVN-US, BSX-US, NURO-US, STJ-US, ABT-US, JNJ-US and BABY-US) that have also reported for this period.


  • Summary numbers: Revenues of USD 0.28 million, Net Earnings of USD -5.00 million.
  • Gross margins widened from -0.59% to 43.73% compared to the same period last year, operating (EBITDA) margins now -2,412.49% from -9,230.64%.
  • Earnings growth from operating margin improvements as well as one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2015-06-30 2015-09-30 2015-12-31 2016-03-31 2016-06-30
Relevant Numbers (Quarterly)
Revenues (mil) 0.08 0.06 0.15 0.07 0.28
Revenue Growth (%YOY) 0 0 0 0 249.37
Earnings (mil) -7.4 -4.15 -6.77 -7.41 -5
Earnings Growth (%YOY) 1.3 27.36 -9.55 -3.27 32.53
Net Margin (%) -9371.85 -6485.42 -4544.3 -10289.95 -1809.84
EPS -1.5 -0.6 -0.95 -0.94 -0.49
Return on Equity (%) -677.18 -361.95 -474.5 -2455.1 N/A
Return on Assets (%) -266.55 -145.04 -203.66 -224.15 -133.91

Access our Ratings and Scores for EnteroMedics, Inc.

Market Share Versus Profits

Revenues History
Earnings History

ETRM-US‘s change in revenue this period compared to the same period last year of 249.37% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that ETRM-US is holding onto its market share. Also, for comparison purposes, revenues changed by 283.33% and earnings by 32.58% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Earnings Growth Analysis

The company’s earnings growth was influenced by year-on-year improvement in gross margins from -0.59% to 43.73% as well as better cost controls. As a result, operating margins (EBITDA margins) rose from -9,230.64% to -2,412.49% compared to the same period last year. For comparison, gross margins were 44.26% and EBITDA margins were -10,419.86% in the last reporting period.

Gross Margin Versus EBITDA Margin

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

ETRM-US‘s improvement in gross margin has been accompanied by an improvement in its balance sheet as well. This suggests that gross margin improvements are likely from operating decisions and not accounting gimmicks. Its working capital days have declined to 1,533.37 days from 3,503.54 days for the same period last year.

Gross Margin Versus Working Capital Days


The company’s earnings growth has also been influenced by the following factors: (1) Improvements in operating (EBIT) margins from -9,292.29% to -2,412.49% and (2) one-time items. The company’s pretax margins are now -1,809.84% compared to -9,371.85% for the same period last year.

EBIT Margin Versus PreTax Margin
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for EnteroMedics, Inc.

Company Profile

EnteroMedics, Inc. is a clinical development stage medical device company that engages in the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. Its initial product Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The company was founded by Mark B. Knudson, Robert S. Nickoloff, Timothy R. Conrad, Katherine S. Tweden and Richard R. Wilson on December 19, 2002 and is headquartered in St. Paul, MN.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of ETRM-US.